Skip to main content

Table 2 Site of initial recurrence by sentinel lymph node status

From: Sentinel lymph node biopsy in melanoma: Our 8-year clinical experience in a single French institute (2002–2009)

 

Number all patients

SLN positive patients

SLN negative patients

p

SLN status

197

44 (22%)

153 (78%)

 

Recurrence:

Yes

34 (17%)

14 (32%)

20 (13%)

0.002

No

163 (83%)

30 (68%)

133 (87%)

 

Site of initial recurrence*:

Local/in transit

17 (50%)

9 (64%)

8 (40%)

NS

Regional lymph node

16 (47%)

6 (43%)

10 (50%)

NS

Distant metastatic

20 (59%)

8 (57%)

14 (70%)

NS

  1. * Some patients may present multiple sites of recurrence.
  2. SLN: sentinel lymph node.
  3. NS: not significant.